Visioneering Technologies, Inc. Logo

Visioneering Technologies, Inc.

VTI.AX

(1.2)
Stock Price

0,14 AUD

-52.34% ROA

-53.42% ROE

-0.82x PER

Market Cap.

4.636.271,73 AUD

3.36% DER

0% Yield

-40.32% NPM

Visioneering Technologies, Inc. Stock Analysis

Visioneering Technologies, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Visioneering Technologies, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.16x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (19%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

4 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

5 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

6 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

7 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

8 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

9 ROE

Negative ROE (-71.66%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

10 ROA

The stock's ROA (-65.33%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

11 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

Visioneering Technologies, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Visioneering Technologies, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Visioneering Technologies, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Visioneering Technologies, Inc. Revenue
Year Revenue Growth
2016 290.558
2017 1.049.000 72.3%
2018 3.294.000 68.15%
2019 8.167.285 59.67%
2019 5.722.000 -42.73%
2020 5.105.000 -12.09%
2021 7.154.000 28.64%
2022 7.285.000 1.8%
2023 11.734.664 37.92%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Visioneering Technologies, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2016 458.705
2017 10.305 -4351.29%
2018 27.286 62.23%
2019 0 0%
2019 3.010.327 100%
2020 2.088.798 -44.12%
2021 2.856.486 26.88%
2022 4.398.245 35.05%
2023 757.072 -480.95%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Visioneering Technologies, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2016 0
2017 3.857.000 100%
2018 4.084.000 5.56%
2019 4.834.428 15.52%
2019 3.387.000 -42.73%
2020 3.319.000 -2.05%
2021 3.194.000 -3.91%
2022 2.425.000 -31.71%
2023 4.571.792 46.96%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Visioneering Technologies, Inc. EBITDA
Year EBITDA Growth
2016 -5.409.170
2017 -15.581.269 65.28%
2018 -16.915.000 7.88%
2019 -17.761.918 4.77%
2019 -12.376.000 -43.52%
2020 -8.848.000 -39.87%
2021 -1.978.000 -347.32%
2022 -5.528.000 64.22%
2023 -6.009.648 8.01%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Visioneering Technologies, Inc. Gross Profit
Year Gross Profit Growth
2016 -886.771
2017 139.000 737.96%
2018 -79.000 275.95%
2019 2.810.448 102.81%
2019 1.969.000 -42.73%
2020 2.224.000 11.47%
2021 2.967.000 25.04%
2022 3.316.000 10.52%
2023 3.330.544 0.44%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Visioneering Technologies, Inc. Net Profit
Year Net Profit Growth
2016 -11.173.036
2017 -16.981.000 34.2%
2018 -16.735.000 -1.47%
2019 -18.008.850 7.07%
2019 -12.617.000 -42.73%
2020 -9.239.000 -36.56%
2021 -2.334.000 -295.84%
2022 -5.854.000 60.13%
2023 -4.859.364 -20.47%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Visioneering Technologies, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2016 0
2017 -11 100%
2018 -8 -42.86%
2019 -6 -40%
2019 -4 -66.67%
2020 -1 -200%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Visioneering Technologies, Inc. Free Cashflow
Year Free Cashflow Growth
2016 -8.167.911
2017 -16.225.526 49.66%
2018 -20.838.985 22.14%
2019 -357 -5853547.47%
2019 -18.205.422 100%
2020 -9.477.339 -92.09%
2021 -10.684.194 11.3%
2022 -5.834.000 -83.14%
2023 -1.401.909 -316.15%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Visioneering Technologies, Inc. Operating Cashflow
Year Operating Cashflow Growth
2016 -7.970.171
2017 -16.020.526 50.25%
2018 -20.821.985 23.06%
2019 0 0%
2019 -18.204.422 100%
2020 -9.453.339 -92.57%
2021 -10.665.194 11.36%
2022 -5.830.000 -82.94%
2023 -1.401.909 -315.86%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Visioneering Technologies, Inc. Capital Expenditure
Year Capital Expenditure Growth
2016 197.740
2017 205.000 3.54%
2018 17.000 -1105.88%
2019 357 -4675.28%
2019 1.000 64.4%
2020 24.000 95.83%
2021 19.000 -26.32%
2022 4.000 -375%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Visioneering Technologies, Inc. Equity
Year Equity Growth
2016 30.733.000
2017 19.186.000 -60.18%
2018 8.965.000 -114.01%
2019 982.000 -812.93%
2020 -1.705.000 157.6%
2021 10.045.000 116.97%
2022 6.294.000 -59.6%
2023 5.758.000 -9.31%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Visioneering Technologies, Inc. Assets
Year Assets Growth
2016 31.143.000
2017 20.555.000 -51.51%
2018 10.379.000 -98.04%
2019 5.830.000 -78.03%
2020 4.987.000 -16.9%
2021 14.913.999 66.56%
2022 9.107.000 -63.76%
2023 7.646.000 -19.11%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Visioneering Technologies, Inc. Liabilities
Year Liabilities Growth
2016 410.000
2017 1.369.000 70.05%
2018 1.414.000 3.18%
2019 4.848.000 70.83%
2020 6.691.999 27.56%
2021 4.869.000 -37.44%
2022 2.813.000 -73.09%
2023 1.888.000 -48.99%

Visioneering Technologies, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.26
Net Income per Share
-0.1
Price to Earning Ratio
-0.82x
Price To Sales Ratio
0.49x
POCF Ratio
-0.76
PFCF Ratio
-1.12
Price to Book Ratio
0.55
EV to Sales
0.19
EV Over EBITDA
-0.4
EV to Operating CashFlow
-0.44
EV to FreeCashFlow
-0.44
Earnings Yield
-1.22
FreeCashFlow Yield
-0.9
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.6
Graham NetNet
0.08

Income Statement Metrics

Net Income per Share
-0.1
Income Quality
1.08
ROE
-0.53
Return On Assets
-0.5
Return On Capital Employed
-0.78
Net Income per EBT
1
EBT Per Ebit
0.84
Ebit per Revenue
-0.48
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0.35
Research & Developement to Revenue
0.07
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.29
Operating Profit Margin
-0.48
Pretax Profit Margin
-0.4
Net Profit Margin
-0.4

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.11
Free CashFlow per Share
-0.11
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.77
Return on Tangible Assets
-0.52
Days Sales Outstanding
36.92
Days Payables Outstanding
26.65
Days of Inventory on Hand
116.8
Receivables Turnover
9.89
Payables Turnover
13.7
Inventory Turnover
3.13
Capex per Share
0

Balance Sheet

Cash per Share
0,08
Book Value per Share
0,15
Tangible Book Value per Share
0.15
Shareholders Equity per Share
0.15
Interest Debt per Share
0.01
Debt to Equity
0.03
Debt to Assets
0.03
Net Debt to EBITDA
0.62
Current Ratio
4.08
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
5882000
Working Capital
0,01 Bil.
Intangibles to Total Assets
0.04
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
2761325.5
Debt to Market Cap
0.04

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Visioneering Technologies, Inc. Dividends
Year Dividends Growth

Visioneering Technologies, Inc. Profile

About Visioneering Technologies, Inc.

Visioneering Technologies, Inc., a medical device company, engages in the design, manufacture, sale, and distribution of contact lenses in North America, Europe, and the Asia-Pacific. The company's flagship product comprises NaturalVue, a multifocal contact lens for adults with presbyopia and children with myopia. Visioneering Technologies, Inc. was incorporated in 2008 and is headquartered in Alpharetta, Georgia.

CEO
Dr. Juan Carlos Aragon
Employee
0
Address
10745 Westside Way
Alpharetta, 30009

Visioneering Technologies, Inc. Executives & BODs

Visioneering Technologies, Inc. Executives & BODs
# Name Age
1 Ms. Layna L. Mendlinger
Global Head of Marketing
70
2 Dr. Juan Carlos Aragon
Chief Executive Officer & Executive Director
70
3 Dr. Kuang-Mon Tuan FAAO, Ph.D.
Chief Medical Officer
70
4 Dr. Richard A. Griffin OD
Founder & Medical Adviser
70
5 Ms. Leanne Ralph AAICD, ACIS, BBus
Company Secretary
70

Visioneering Technologies, Inc. Competitors

Uscom Limited Logo
Uscom Limited

UCM.AX

(1.0)
ImpediMed Limited Logo
ImpediMed Limited

IPD.AX

(0.8)
Adherium Limited Logo
Adherium Limited

ADR.AX

(1.5)
Respiri Limited Logo
Respiri Limited

RSH.AX

(1.0)
Rhinomed Limited Logo
Rhinomed Limited

RNO.AX

(1.0)